CelLBxHealth shares jump on partnership with AstraZeneca

Fri, 29th May 2026 10:31

(Alliance News) - CelLBxHealth PLC on Friday disclosed that it has entered a partnership with AstraZeneca PLC.

In response, shares in the Guildford, England-based liquid biopsy company, formerly called Angle PLC, jumped 54% to 2.65 pence each on Friday Morning in London.

Shares in Cambridge, England-based drug developer AstraZeneca were up 0.9% to 13,864.00p.

CelLBxHealth has entered into a master services agreement that makes it "a qualified service provider to AstraZeneca, enabling the company to support drug discovery and development through [circulating tumour cell] powered analytics of clinical trial samples using the Parsortix platform".

Earlier this month, CelLBxHealth noted that it was in the final stages of a deal with a top-ten global pharmaceutical company.

CelLBxHealth Chief Executive Peter Collins said the agreement "enables AstraZeneca to access our capabilities across their development pipeline. We look forward to delivering strong and productive outcomes through this framework."

CelLBxHealth in mid-May forecast 2026 revenue of at least GBP2.1 million, which would represent growth of around 50% from 2025, supported by contracts and expected sales conversions.

This follows cost-saving measures at the company, which cut 5 more jobs in the three months ended March 31, after a 60% headcount reduction in 2025.

CelLBxHealth expects to reduce annual cash operating costs in 2026 by more than GBP6.6 million. Further planned cost reductions in the second quarter are expected to generate an additional GBP100,000 in savings.

Cash at March 31 stood at GBP4.3 million, in line with company expectations and reflecting one-off restructuring costs.

By Holly Munks, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Corporate News Pharmaceuticals Health Care